Free Trial
→ The Trump Dump is starting; Get out of stocks now? (From Paradigm Press) (Ad) Buy CRNX Stock  Free CRNX Stock Alerts

Crinetics Pharmaceuticals (CRNX) Financials

Crinetics Pharmaceuticals logo
$29.76 -0.35 (-1.16%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$30.02 +0.26 (+0.87%)
As of 05/23/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Crinetics Pharmaceuticals

Annual Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Income / (Loss) Attributable to Common Shareholders		 -298 -215 -164 -108 -74 -50 -27 -9.16 -6.02
Consolidated Net Income / (Loss)		 -298 -215 -164 -108 -74 -50 -27 -9.16 -6.02
Net Income / (Loss) Continuing Operations		 -298 -215 -164 -108 -74 -50 -27 -9.16 -6.02
Total Pre-Tax Income 		-298 -215 -164 -108 -74 -50 -27 -9.16 -6.02
Total Operating Income		 -339 -223 -168 -108 -75 -54 -29 -9.13 -6.04
Total Gross Profit		 1.04 4.01 4.74 1.08 0.14 1.19 2.43 2.05 0.59
Total Revenue		 1.04 4.01 4.74 1.08 0.14 1.19 2.43 2.05 0.59
Operating Revenue		 1.04 4.01 4.74 1.08 0.14 1.19 2.43 2.05 0.59
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 340 227 173 109 75 55 31 11 6.63
Selling, General & Admin Expense		 100 58 42 25 18 14 6.66 1.94 1.53
Research & Development Expense		 240 169 130 84 57 42 24 9.23 5.10
Total Other Income / (Expense), net		 40 8.08 3.96 0.16 0.99 3.41 1.60 -0.03 0.03
Interest & Investment Income		 41 8.24 3.31 0.16 0.99 3.46 1.75 0.03 0.04
Other Income / (Expense), net		 -0.52 -0.16 0.66 0.00 0.00 -0.05 -0.15 -0.05 -0.00
Basic Earnings per Share		 ($3.69) ($3.69) ($3.15) ($2.80) ($2.42) ($2.09) ($2.23) ($6.68) ($5.96)
Weighted Average Basic Shares Outstanding		 80.78M 58.07M 51.98M 38.44M 30.45M 24.18M 12.14M 1.37M 1.01M
Diluted Earnings per Share		 ($3.69) ($3.69) ($3.15) ($2.80) ($2.42) ($2.09) ($2.23) ($6.68) ($5.96)
Weighted Average Diluted Shares Outstanding		 80.78M 58.07M 51.98M 38.44M 30.45M 24.18M 12.14M 1.37M 1.01M
Weighted Average Basic & Diluted Shares Outstanding		 93.05M 69.60M 53.91M 38.44M 30.45M 24.18M 12.14M 1.37M 1.01M

Quarterly Income Statements for Crinetics Pharmaceuticals

This table shows Crinetics Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -97 -83 -75 -74 -67 -61 -57 -51 -46 -45 -42
Consolidated Net Income / (Loss)		 -97 -81 -77 -74 -67 -60 -57 -51 -46 -45 -42
Net Income / (Loss) Continuing Operations		 -97 -81 -77 -74 -67 -60 -57 -51 -46 -45 -42
Total Pre-Tax Income 		-97 -81 -77 -74 -67 -60 -57 -51 -46 -45 -42
Total Operating Income		 -111 -95 -88 -83 -74 -63 -59 -53 -48 -48 -43
Total Gross Profit		 0.36 - 0.00 0.40 0.64 - 0.35 0.99 2.68 0.71 0.46
Total Revenue		 0.36 - 0.00 0.40 0.64 - 0.35 0.99 2.68 0.71 0.46
Operating Revenue		 0.36 - 0.00 0.40 0.64 - 0.35 0.99 2.68 0.71 0.46
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 112 95 88 83 74 63 59 54 51 48 44
Selling, General & Admin Expense		 36 28 26 25 21 17 15 13 12 11 12
Research & Development Expense		 76 67 62 58 53 46 44 41 38 37 32
Total Other Income / (Expense), net		 15 14 11 8.73 7.07 2.56 1.52 2.02 1.98 2.57 1.53
Interest & Investment Income		 15 14 11 8.74 6.85 2.52 1.57 2.11 2.04 1.90 1.50
Other Income / (Expense), net		 -0.20 - -0.04 -0.01 - - -0.05 -0.09 - - 0.03
Basic Earnings per Share		 ($1.04) ($0.86) ($0.96) ($0.94) ($0.93) ($0.89) ($1.01) ($0.94) ($0.85) ($0.83) ($0.78)
Weighted Average Basic Shares Outstanding		 93.10M 80.78M 80.09M 79.01M 72.29M 58.07M 56.81M 54.28M 53.91M 51.98M 53.77M
Diluted Earnings per Share		 ($1.04) ($0.86) ($0.96) ($0.94) ($0.93) ($0.89) ($1.01) ($0.94) ($0.85) ($0.83) ($0.78)
Weighted Average Diluted Shares Outstanding		 93.10M 80.78M 80.09M 79.01M 72.29M 58.07M 56.81M 54.28M 53.91M 51.98M 53.77M
Weighted Average Basic & Diluted Shares Outstanding		 93.68M 93.05M 92.74M 80.04M 78.86M 69.60M 66.80M 54.69M 54.03M 53.91M 53.81M

Annual Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Net Change in Cash & Equivalents		 210 22 -167 108 53 -4.65 31 2.04 -5.71
Net Cash From Operating Activities		 -226 -166 -115 -89 -62 -46 -19 -9.48 -5.47
Net Cash From Continuing Operating Activities		 -226 -166 -115 -89 -62 -46 -19 -9.48 -5.47
Net Income / (Loss) Continuing Operations		 -298 -215 -164 -108 -74 -50 -27 -9.16 -6.02
Consolidated Net Income / (Loss)		 -298 -215 -164 -108 -74 -50 -27 -9.16 -6.02
Depreciation Expense		 2.79 1.10 0.98 0.92 0.95 0.89 0.47 0.13 0.09
Amortization Expense		 -15 -6.27 0.03 0.42 -0.23 -1.23 -0.43 - -
Non-Cash Adjustments To Reconcile Net Income		 73 45 29 17 11 6.52 2.32 0.27 0.27
Changes in Operating Assets and Liabilities, net		 12 8.04 19 1.10 0.38 -2.13 5.30 -0.72 0.19
Net Cash From Investing Activities		 -575 -200 -174 -56 0.22 42 -119 -0.30 -0.19
Net Cash From Continuing Investing Activities		 -575 -200 -174 -56 0.22 42 -119 -0.30 -0.19
Purchase of Property, Plant & Equipment		 -3.84 -4.69 -1.66 -0.44 -0.19 -0.49 -1.06 -0.30 -0.19
Purchase of Investments		 -1,147 -528 -330 -125 -136 -108 -118 - -
Sale and/or Maturity of Investments		 576 337 157 69 136 150 0.00 - -
Net Cash From Financing Activities		 1,010 389 122 253 115 0.07 170 12 -0.05
Net Cash From Continuing Financing Activities		 1,010 389 122 253 115 0.07 170 12 -0.05
Repayment of Debt		 0.00 - - 0.00 - - - -0.21 -0.05
Issuance of Common Equity		 970 369 117 250 114 0.00 106 - -
Other Financing Activities, net		 40 20 4.72 3.14 0.29 0.13 0.45 0.07 -

Quarterly Cash Flow Statements for Crinetics Pharmaceuticals

This table details how cash moves in and out of Crinetics Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -170 -53 15 -94 341 -88 103 -1.64 8.52 1.76 -31
Net Cash From Operating Activities		 -88 -65 -63 -46 -53 -39 -41 -46 -41 -35 -38
Net Cash From Continuing Operating Activities		 -88 -65 -63 -46 -53 -39 -41 -46 -41 -35 -39
Net Income / (Loss) Continuing Operations		 -97 -81 -77 -74 -67 -60 -57 -51 -46 -45 -42
Consolidated Net Income / (Loss)		 -97 -81 -77 -74 -67 -60 -57 -51 -46 -45 -42
Depreciation Expense		 0.93 0.79 0.77 0.75 0.47 0.26 0.27 0.28 0.28 0.28 0.25
Amortization Expense		 -4.38 -4.16 -3.51 -3.41 -3.85 -3.58 -1.25 -0.91 -0.53 -0.35 -0.13
Non-Cash Adjustments To Reconcile Net Income		 21 20 19 20 15 17 12 10 6.21 7.49 7.51
Changes in Operating Assets and Liabilities, net		 -9.54 -0.31 -2.15 11 2.69 8.30 4.85 -4.42 -0.69 2.37 -4.21
Net Cash From Investing Activities		 -86 -542 21 -54 0.31 -87 -193 31 49 37 6.82
Net Cash From Continuing Investing Activities		 -86 -542 21 -54 0.31 -87 -193 31 49 37 6.82
Purchase of Property, Plant & Equipment		 -1.24 -1.03 -0.53 -0.96 -1.33 -0.94 -3.50 -0.24 -0.02 -0.27 -0.68
Purchase of Investments		 -391 -725 -130 -192 -100 -168 -278 -59 -23 -34 -49
Sale and/or Maturity of Investments		 306 184 151 139 101 87 88 91 71 71 56
Net Cash From Financing Activities		 4.44 554 57 5.50 394 38 338 13 0.48 0.12 1.08
Net Cash From Continuing Financing Activities		 4.44 554 57 5.50 394 38 338 13 0.48 0.12 1.08
Repayment of Debt		 0.00 - - - - - - - 0.00 - -
Issuance of Common Equity		 0.00 544 47 -4.31 383 29 329 11 0.00 - -0.01
Other Financing Activities, net		 4.44 9.54 11 9.81 10 9.17 8.92 1.35 0.48 0.12 1.09

Annual Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2017
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2017
Total Assets		 1,435 635 352 351 183 130 16
Total Current Assets		 1,375 574 345 345 177 123 15
Cash & Equivalents		 265 55 33 201 93 40 14
Restricted Cash		 0.50 0.00 - - - - -
Short-Term Investments		 1,090 504 302 133 78 78 -
Prepaid Expenses		 21 16 11 11 6.61 4.95 0.97
Plant, Property, & Equipment, net		 12 11 3.50 2.83 3.18 3.95 0.40
Total Noncurrent Assets		 47 50 3.49 3.47 2.77 3.09 0.03
Long-Term Investments		 0.00 0.47 0.00 1.01 - - -
Other Noncurrent Operating Assets		 47 50 3.49 2.46 2.77 3.09 0.03
Total Liabilities & Shareholders' Equity		 1,435 635 352 351 183 130 16
Total Liabilities		 110 96 36 19 15 13 0.92
Total Current Liabilities		 60 44 28 16 10 8.34 0.90
Accounts Payable		 21 23 15 8.47 5.59 5.50 0.40
Accrued Expenses		 29 15 9.08 6.59 4.07 2.12 0.18
Current Deferred Revenue		 2.18 2.06 2.24 0.00 - - -
Other Current Liabilities		 7.15 4.17 1.05 0.94 0.84 0.72 -
Total Noncurrent Liabilities		 50 52 8.13 3.08 4.04 4.90 0.02
Noncurrent Deferred Revenue		 4.70 4.75 6.10 0.00 - - 0.02
Other Noncurrent Operating Liabilities		 45 48 2.02 3.07 4.01 4.85 -
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,325 539 316 332 169 117 -15
Total Preferred & Common Equity		 1,325 539 316 332 169 117 -15
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,325 539 316 332 169 117 -15
Common Stock		 2,276 1,192 759 608 337 211 1.24
Retained Earnings		 -952 -654 -439 -275 -168 -94 -16
Accumulated Other Comprehensive Income / (Loss)		 0.96 0.98 -3.93 -0.38 0.03 0.15 -

Quarterly Balance Sheets for Crinetics Pharmaceuticals

This table presents Crinetics Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 1,361 937 936 978 642 293 314 385
Total Current Assets		 1,291 878 875 917 576 285 305 378
Cash & Equivalents		 95 317 302 396 143 40 41 31
Restricted Cash		 0.50 - - - - - - -
Short-Term Investments		 1,180 545 561 505 412 225 255 337
Prepaid Expenses		 16 15 12 16 21 20 9.28 9.96
Plant, Property, & Equipment, net		 13 12 12 12 9.76 3.22 3.27 3.56
Total Noncurrent Assets		 58 48 49 49 56 5.22 5.34 2.99
Other Noncurrent Operating Assets		 58 48 49 49 51 5.22 5.34 2.99
Total Liabilities & Shareholders' Equity		 1,361 937 936 978 642 293 314 385
Total Liabilities		 107 104 105 103 94 39 34 34
Total Current Liabilities		 57 54 54 52 40 33 26 25
Accounts Payable		 32 18 24 29 22 21 16 13
Accrued Expenses		 17 26 20 15 13 8.60 6.83 7.72
Current Deferred Revenue		 2.21 1.69 2.56 2.46 1.66 2.08 2.12 2.32
Other Current Liabilities		 6.88 7.41 7.45 5.79 3.99 1.11 1.08 1.02
Total Noncurrent Liabilities		 50 51 50 51 53 6.53 7.36 8.95
Noncurrent Deferred Revenue		 4.31 5.20 4.32 4.74 5.14 5.07 5.62 6.65
Other Noncurrent Operating Liabilities		 46 46 46 47 48 1.46 1.74 2.30
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,254 833 831 875 548 254 280 351
Total Preferred & Common Equity		 1,254 833 831 875 548 254 280 351
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 1,254 833 831 875 548 254 280 351
Common Stock		 2,301 1,702 1,626 1,595 1,142 792 768 751
Retained Earnings		 -1,049 -872 -795 -721 -594 -536 -485 -394
Accumulated Other Comprehensive Income / (Loss)		 2.00 2.04 -0.19 0.15 -0.87 -1.71 -2.51 -5.01

Annual Metrics And Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016
Growth Metrics		 - - - - - - - - -
Revenue Growth		 -74.11% -15.28% 339.42% 659.15% -88.10% -50.86% 18.73% 247.20% 0.00%
EBITDA Growth		 -54.22% -37.14% -56.27% -43.28% -36.90% -88.11% -218.61% -51.97% 0.00%
EBIT Growth		 -52.34% -33.21% -55.27% -43.69% -39.11% -86.68% -214.58% -51.78% 0.00%
NOPAT Growth		 -52.22% -32.60% -55.88% -43.69% -39.24% -87.50% -214.56% -51.01% 0.00%
Net Income Growth		 -39.10% -30.88% -52.28% -45.83% -46.39% -85.96% -196.11% -52.13% 0.00%
EPS Growth		 0.00% -17.14% -12.50% -15.70% -15.79% 6.28% 66.62% -12.08% 0.00%
Operating Cash Flow Growth		 -35.88% -44.36% -30.05% -42.82% -33.73% -138.35% -105.29% -73.35% 0.00%
Free Cash Flow Firm Growth		 -47.63% -50.70% -37.03% -44.09% -42.08% -85.76% -185.26% 0.00% 0.00%
Invested Capital Growth		 -49.43% -10.07% -552.61% -41.41% -56.50% 0.00% -100.00% 0.00% 0.00%
Revenue Q/Q Growth		 0.00% -15.01% -23.40% 1,418.31% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 -10.24% -8.84% -11.02% -9.21% -17,009.34% -6,361.43% 0.00% 0.00% 0.00%
EBIT Q/Q Growth		 -10.63% -7.35% -10.59% -9.23% 0.00% 0.00% 0.00% 0.00% 0.00%
NOPAT Q/Q Growth		 -10.46% -7.28% -11.02% -9.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Income Q/Q Growth		 -7.38% -7.57% -9.48% -9.29% 0.00% 0.00% 0.00% 0.00% 0.00%
EPS Q/Q Growth		 0.81% -1.65% -5.00% -2.19% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Cash Flow Q/Q Growth		 -13.09% -2.03% -11.96% -8.53% -4.18% -19.10% -21.92% 0.00% 0.00%
Free Cash Flow Firm Q/Q Growth		 -15.63% -2.21% -15.35% -8.26% -1,931.36% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -0.26% -72.07% -6.52% -1,146.42% -592.71% 41.72% 0.00% 0.00% 0.00%
Profitability Metrics		 - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -33,832.44% -5,680.04% -3,508.72% -9,866.23% -52,276.06% -4,545.18% -1,187.19% -442.40% -1,010.70%
Operating Margin		 -32,613.47% -5,547.17% -3,544.06% -9,990.91% -52,783.80% -4,512.32% -1,182.45% -446.31% -1,026.15%
EBIT Margin		 -32,663.43% -5,551.13% -3,530.19% -9,990.91% -52,783.80% -4,516.51% -1,188.76% -448.66% -1,026.32%
Profit (Net Income) Margin		 -28,720.69% -5,345.85% -3,460.38% -9,985.25% -51,980.28% -4,226.49% -1,116.76% -447.78% -1,021.90%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.09% 99.80% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 87.93% 96.30% 98.02% 99.85% 98.68% 93.58% 93.94% 99.80% 99.57%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,270.37% -2,629.18% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,171.47% -2,590.17% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 7,900.91% 2,504.41% 0.00%
Return on Equity (ROE)		 -32.02% -50.16% -50.57% -42.98% -51.61% -86.09% -369.46% -124.77% 0.00%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -8,070.37% -2,829.18% 0.00%
Operating Return on Assets (OROA)		 -32.79% -45.12% -47.56% -40.30% -47.77% -82.66% -370.09% -58.82% 0.00%
Return on Assets (ROA)		 -28.83% -43.45% -46.62% -40.28% -47.04% -77.35% -347.67% -58.71% 0.00%
Return on Common Equity (ROCE)		 -32.02% -50.16% -50.57% -42.98% -51.61% -86.09% 378.12% 127.70% 0.00%
Return on Equity Simple (ROE_SIMPLE)		 -22.52% -39.79% -51.82% -32.43% -43.70% -43.04% 0.00% 60.96% 0.00%
Net Operating Profit after Tax (NOPAT)		 -237 -156 -118 -75 -52 -38 -20 -6.39 -4.23
NOPAT Margin		 -22,829.43% -3,883.02% -2,480.84% -6,993.64% -36,948.66% -3,158.63% -827.72% -312.42% -718.30%
Net Nonoperating Expense Percent (NNEP)		 -6.40% -13.14% -13.87% -12.76% -14.76% -21.52% -98.90% -39.01% 0.00%
Return On Investment Capital (ROIC_SIMPLE)		 -17.90% -28.90% -37.15% - - - - - -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 9,599.33% 1,447.65% 894.95% 2,275.05% 12,694.37% 1,133.19% 274.26% 94.82% 260.27%
R&D to Revenue		 23,114.15% 4,199.53% 2,749.10% 7,815.86% 40,139.44% 3,479.13% 1,008.20% 451.49% 865.87%
Operating Expenses to Revenue		 32,713.47% 5,647.17% 3,644.06% 10,099.81% 52,728.17% 4,612.32% 1,282.45% 546.31% 1,126.15%
Earnings before Interest and Taxes (EBIT)		 -339 -223 -167 -108 -75 -54 -29 -9.18 -6.05
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -352 -228 -166 -106 -74 -54 -29 -9.05 -5.95
Valuation Ratios		 - - - - - - - - -
Price to Book Value (P/BV)		 2.08 3.56 3.11 4.07 2.75 5.19 0.00 0.00 0.00
Price to Tangible Book Value (P/TBV)		 2.08 3.56 3.11 4.07 2.75 5.19 0.00 0.00 0.00
Price to Revenue (P/Rev)		 2,652.90 477.97 207.88 1,251.83 3,271.37 509.42 296.90 49.88 173.17
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 241.79 0.00
Enterprise Value to Revenue (EV/Rev)		 1,349.17 338.66 137.28 941.33 2,067.99 410.18 296.90 57.46 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.03 -1.04 -1.03 -1.01 -1.01 -1.01 -0.97 -0.97 0.00
Leverage Ratio		 1.11 1.15 1.08 1.07 1.10 1.11 1.06 1.06 0.00
Compound Leverage Factor		 0.98 1.11 1.06 1.07 1.08 1.04 1.00 1.06 0.00
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 202.34% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% -102.34% 0.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 14.46 10.37 14.26 41.47 17.65 26.24 0.00 64.35 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 202.34% 202.34% 0.00%
Liquidity Ratios		 - - - - - - - - -
Current Ratio		 23.04 13.07 12.45 21.55 16.92 14.79 0.00 16.91 0.00
Quick Ratio		 22.69 12.71 12.06 20.86 16.29 14.20 0.00 15.82 0.00
Cash Flow Metrics		 - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -227 -154 -102 -75 -52 -36 -20 -6.87 0.00
Operating Cash Flow to CapEx		 -5,878.51% -3,547.50% -6,956.82% -20,318.35% -33,347.85% -9,427.03% -1,837.49% -3,118.09% -2,877.89%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -859.36 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,184.88 -497.09
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,222.88 -514.36
Efficiency Ratios		 - - - - - - - - -
Asset Turnover		 0.00 0.01 0.01 0.00 0.00 0.02 0.31 0.13 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.09 0.56 1.50 0.36 0.04 0.00 0.00 5.11 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - -
Invested Capital		 -30 -20 -18 -2.77 -1.96 -1.25 0.00 0.49 0.00
Invested Capital Turnover		 -0.04 -0.21 -0.45 -0.46 -0.09 -1.90 9.99 8.42 0.00
Increase / (Decrease) in Invested Capital		 -9.85 -1.82 -15 -0.81 -0.71 -1.25 -0.49 0.49 0.00
Enterprise Value (EV)		 1,402 1,359 650 1,015 294 489 721 118 0.00
Market Capitalization		 2,756 1,918 985 1,349 465 608 721 102 102
Book Value per Share		 $14.29 $8.07 $5.88 $6.99 $5.13 $4.84 $0.00 ($10.96) $0.00
Tangible Book Value per Share		 $14.29 $8.07 $5.88 $6.99 $5.13 $4.84 $0.00 ($10.96) $0.00
Total Capital		 1,325 539 316 332 169 117 0.00 15 0.00
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,355 -559 -334 -335 -171 -118 0.00 -14 0.00
Capital Expenditures (CapEx)		 3.84 4.69 1.66 0.44 0.19 0.49 1.06 0.30 0.19
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -39 -28 -17 -4.98 -3.88 -3.39 0.00 0.08 0.00
Debt-free Net Working Capital (DFNWC)		 1,316 530 317 329 167 115 0.00 14 0.00
Net Working Capital (NWC)		 1,316 530 317 329 167 115 0.00 14 0.00
Net Nonoperating Expense (NNE)		 61 59 46 32 21 13 7.02 2.77 1.79
Net Nonoperating Obligations (NNO)		 -1,355 -559 -334 -335 -171 -118 0.00 -14 0.00
Total Depreciation and Amortization (D&A)		 -12 -5.17 1.02 1.34 0.72 -0.34 0.04 0.13 0.09
Debt-free, Cash-free Net Working Capital to Revenue		 -3,740.62% -706.30% -358.12% -462.15% -2,730.28% -284.41% 0.00% 3.72% 0.00%
Debt-free Net Working Capital to Revenue		 126,631.76% 13,212.33% 6,701.73% 30,493.97% 117,607.75% 9,639.48% 0.00% 697.70% 0.00%
Net Working Capital to Revenue		 126,631.76% 13,212.33% 6,701.73% 30,493.97% 117,607.75% 9,639.48% 0.00% 697.70% 0.00%
Earnings Adjustments		 - - - - - - - - -
Adjusted Basic Earnings per Share		 ($3.69) ($3.69) ($3.15) ($2.80) ($2.42) $0.00 ($2.23) ($6.68) ($5.96)
Adjusted Weighted Average Basic Shares Outstanding		 80.78M 58.07M 51.98M 47.78B 33.03M 0.00 24.10M 1.37M 1.01M
Adjusted Diluted Earnings per Share		 ($3.69) ($3.69) ($3.15) ($2.80) ($2.42) $0.00 ($2.23) ($6.68) ($5.96)
Adjusted Weighted Average Diluted Shares Outstanding		 80.78M 58.07M 51.98M 47.78B 33.03M 0.00 24.10M 1.37M 1.01M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($2.80) ($2.42) $0.00 ($2.23) ($6.68) ($5.96)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 93.05M 69.60M 53.91M 38.44M 30.45M 0.00 12.14M 1.37M 1.01M
Normalized Net Operating Profit after Tax (NOPAT)		 -237 -156 -118 -75 -52 -38 -20 -6.39 -4.23
Normalized NOPAT Margin		 -22,829.43% -3,883.02% -2,480.84% -6,993.64% -36,948.66% -3,158.63% -827.72% -312.42% -718.30%
Pre Tax Income Margin		 -28,720.69% -5,345.85% -3,460.38% -9,976.35% -52,085.92% -4,226.49% -1,116.76% -447.78% -1,021.90%
Debt Service Ratios		 - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,146.88 -549.55
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -798.61 -384.62
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1,184.88 -566.82
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -836.61 -401.89
Payout Ratios		 - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Crinetics Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Crinetics Pharmaceuticals' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -43.59% 0.00% -100.00% -59.62% -76.11% 0.00% -24.45% 125.06% -14.44% -34.23% 0.00%
EBITDA Growth		 -49.13% -48.71% -50.95% -59.08% -59.47% -38.53% -38.55% -25.99% -45.05% -56.32% -57.44%
EBIT Growth		 -51.27% -51.21% -48.80% -55.97% -53.26% -31.76% -35.94% -23.33% -41.90% -53.96% -56.17%
NOPAT Growth		 -51.51% -51.21% -48.87% -56.21% -53.26% -31.76% -35.72% -23.12% -41.83% -53.96% -56.27%
Net Income Growth		 -44.59% -34.11% -33.71% -45.27% -45.52% -33.58% -37.05% -20.30% -32.83% -46.10% -50.53%
EPS Growth		 -11.83% 3.37% 4.95% 0.00% -9.41% -7.23% -29.49% -16.05% -16.44% -22.06% -6.85%
Operating Cash Flow Growth		 -67.35% -67.92% -51.97% 0.26% -29.81% -9.40% -7.43% -63.48% -200.66% -53.75% -49.88%
Free Cash Flow Firm Growth		 -102.23% -34.34% 7.18% 26.22% -19.38% -134.00% -254.77% -384.79% -325.66% 13.67% 31.91%
Invested Capital Growth		 20.76% -49.43% -156.46% -209.13% -64.82% -10.07% 31.87% 53.39% 5.71% -552.61% -6,511.32%
Revenue Q/Q Growth		 0.00% 0.00% -100.00% -37.66% 0.00% 0.00% -64.98% -63.12% 277.86% 54.80% 4.33%
EBITDA Q/Q Growth		 -17.26% -8.33% -6.00% -11.12% -16.55% -9.96% -11.70% -11.39% -1.26% -9.97% -1.58%
EBIT Q/Q Growth		 -17.80% -7.87% -6.08% -12.60% -17.35% -6.15% -11.20% -10.65% -0.89% -9.51% -0.88%
NOPAT Q/Q Growth		 -17.58% -7.91% -6.06% -12.59% -17.35% -6.24% -11.29% -10.46% -0.89% -9.44% -0.95%
Net Income Q/Q Growth		 -20.07% -4.90% -3.74% -10.65% -11.37% -4.59% -12.71% -10.84% -2.23% -7.31% 1.06%
EPS Q/Q Growth		 -20.93% 10.42% -2.13% -1.08% -4.49% 11.88% -7.45% -10.59% -2.41% -6.41% 3.70%
Operating Cash Flow Q/Q Growth		 -36.77% -2.95% -37.72% 13.70% -37.23% 6.83% 9.61% -12.32% -15.65% 8.50% -37.54%
Free Cash Flow Firm Q/Q Growth		 -47.65% -30.29% -19.84% 12.28% 1.91% 9.98% 4.75% -41.93% -92.27% -36.48% -30.16%
Invested Capital Q/Q Growth		 30.71% -0.26% 7.77% -23.67% -30.67% -72.07% -11.17% 34.06% 12.74% -6.52% 23.95%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -31,872.30% 0.00% 0.00% -21,416.29% -12,015.94% 0.00% -17,341.91% -5,436.94% -1,800.11% -6,717.49% -9,456.11%
Operating Margin		 -30,860.11% 0.00% 0.00% -20,747.62% -11,488.91% 0.00% -17,045.38% -5,363.87% -1,790.89% -6,707.48% -9,487.77%
EBIT Margin		 -30,916.34% 0.00% 0.00% -20,750.88% -11,488.91% 0.00% -17,060.69% -5,373.08% -1,790.89% -6,707.48% -9,481.44%
Profit (Net Income) Margin		 -26,807.20% 0.00% 0.00% -18,560.15% -10,457.81% 0.00% -16,606.36% -5,159.82% -1,716.87% -6,345.70% -9,153.93%
Tax Burden Percent		 100.00% 99.69% 100.00% 100.00% 100.38% 99.91% 100.00% 100.00% 100.12% 99.89% 100.00%
Interest Burden Percent		 86.71% 85.33% 87.47% 89.44% 90.68% 96.00% 97.34% 96.03% 95.75% 94.71% 96.55%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -30.84% -32.02% -40.26% -47.66% -40.76% -50.16% -44.36% -57.44% -60.09% -50.57% -54.95%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -20.09% 0.00% 0.00% -46.78% -35.10% 0.00% -156.97% -72.65% -23.71% -90.37% -197.34%
Return on Assets (ROA)		 -17.42% 0.00% 0.00% -41.84% -31.95% 0.00% -152.79% -69.77% -22.73% -85.49% -190.52%
Return on Common Equity (ROCE)		 -30.84% -32.02% -40.26% -47.66% -40.76% -50.16% -44.36% -57.44% -60.09% -50.57% -54.95%
Return on Equity Simple (ROE_SIMPLE)		 -26.18% 0.00% -33.36% -31.12% -26.91% 0.00% -36.41% -72.36% -62.53% 0.00% -42.61%
Net Operating Profit after Tax (NOPAT)		 -78 -66 -61 -58 -51 -44 -41 -37 -34 -33 -30
NOPAT Margin		 -21,602.08% 0.00% 0.00% -14,523.33% -8,042.23% 0.00% -11,931.76% -3,754.71% -1,253.62% -4,695.23% -6,641.44%
Net Nonoperating Expense Percent (NNEP)		 -1.73% -1.49% -2.16% -2.86% -2.58% -3.63% -3.49% -4.13% -4.03% -3.50% -4.10%
Return On Investment Capital (ROIC_SIMPLE)		 -6.22% -5.01% - - - -8.14% - - - -10.52% -
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 9,841.00% 0.00% 0.00% 6,225.06% 3,254.38% 0.00% 4,475.14% 1,350.51% 454.98% 1,590.13% 2,603.71%
R&D to Revenue		 21,119.11% 0.00% 0.00% 14,622.56% 8,334.53% 0.00% 12,670.23% 4,113.36% 1,435.91% 5,217.35% 6,984.06%
Operating Expenses to Revenue		 30,960.11% 0.00% 0.00% 20,847.62% 11,588.91% 0.00% 17,145.38% 5,463.87% 1,890.89% 6,807.48% 9,587.77%
Earnings before Interest and Taxes (EBIT)		 -112 -95 -88 -83 -74 -63 -59 -53 -48 -48 -43
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -115 -98 -91 -85 -77 -66 -60 -54 -48 -48 -43
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.44 2.08 3.31 2.91 2.88 3.56 2.93 3.82 3.09 3.11 3.00
Price to Tangible Book Value (P/TBV)		 1.44 2.08 3.31 2.91 2.88 3.56 2.93 3.82 3.09 3.11 3.00
Price to Revenue (P/Rev)		 2,379.08 2,652.90 2,651.34 1,743.38 1,278.36 477.97 339.53 200.96 202.05 207.88 170.72
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 701.95 1,349.17 1,821.05 1,120.31 821.94 338.66 221.08 146.24 132.94 137.28 111.15
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -1.03 -1.03 -1.04 -1.04 -1.04 -1.03 -1.05 -1.06 -1.03 -1.03
Leverage Ratio		 1.10 1.11 1.14 1.13 1.12 1.15 1.14 1.12 1.11 1.08 1.09
Compound Leverage Factor		 0.95 0.95 1.00 1.01 1.01 1.11 1.11 1.07 1.06 1.03 1.05
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 9.85 15.02 15.28 13.40 14.45 11.20 9.67 12.78 13.84 15.39 18.22
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 22.53 23.04 16.38 16.09 17.72 13.07 14.23 8.73 11.60 12.45 15.41
Quick Ratio		 22.23 22.69 16.11 15.87 17.40 12.71 13.71 8.11 11.25 12.06 15.00
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -83 -56 -43 -36 -41 -42 -47 -49 -35 -18 -13
Operating Cash Flow to CapEx		 -7,138.98% -6,285.13% -11,898.30% -4,776.65% -3,968.17% -4,119.25% -1,181.11% -19,297.47% -254,487.50% -12,849.27% -5,642.08%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.02
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.06 0.09 0.10 0.18 0.26 0.56 0.71 1.52 1.44 1.50 1.91
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -21 -30 -30 -32 -26 -20 -12 -10 -16 -18 -17
Invested Capital Turnover		 -0.03 -0.04 -0.05 -0.07 -0.09 -0.21 -0.33 -0.30 -0.26 -0.45 -0.74
Increase / (Decrease) in Invested Capital		 5.40 -9.85 -18 -22 -10 -1.82 5.41 12 0.96 -15 -17
Enterprise Value (EV)		 533 1,402 1,892 1,552 1,623 1,359 1,044 707 570 650 687
Market Capitalization		 1,808 2,756 2,755 2,415 2,523 1,918 1,603 971 866 985 1,056
Book Value per Share		 $13.48 $14.29 $10.41 $10.53 $12.57 $8.07 $10.02 $4.70 $5.20 $5.88 $6.54
Tangible Book Value per Share		 $13.48 $14.29 $10.41 $10.53 $12.57 $8.07 $10.02 $4.70 $5.20 $5.88 $6.54
Total Capital		 1,254 1,325 833 831 875 539 548 254 280 316 351
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1,275 -1,355 -863 -863 -901 -559 -559 -265 -296 -334 -368
Capital Expenditures (CapEx)		 1.24 1.03 0.53 0.96 1.33 0.94 3.50 0.24 0.02 0.27 0.68
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -41 -39 -39 -43 -36 -28 -19 -12 -17 -17 -15
Debt-free Net Working Capital (DFNWC)		 1,234 1,316 824 820 865 530 535 252 279 317 354
Net Working Capital (NWC)		 1,234 1,316 824 820 865 530 535 252 279 317 354
Net Nonoperating Expense (NNE)		 19 14 15 16 15 16 16 14 12 12 12
Net Nonoperating Obligations (NNO)		 -1,275 -1,355 -863 -863 -901 -559 -559 -265 -296 -334 -368
Total Depreciation and Amortization (D&A)		 -3.45 -3.38 -2.74 -2.66 -3.37 -3.32 -0.97 -0.63 -0.25 -0.07 0.12
Debt-free, Cash-free Net Working Capital to Revenue		 -5,378.95% -3,740.62% -3,719.25% -3,072.49% -1,798.38% -706.30% -409.91% -255.05% -397.67% -358.12% -236.01%
Debt-free Net Working Capital to Revenue		 162,334.74% 126,631.76% 79,309.43% 59,234.58% 43,843.01% 13,212.33% 11,336.23% 5,217.21% 6,513.00% 6,701.73% 5,720.68%
Net Working Capital to Revenue		 162,334.74% 126,631.76% 79,309.43% 59,234.58% 43,843.01% 13,212.33% 11,336.23% 5,217.21% 6,513.00% 6,701.73% 5,720.68%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.04) ($0.86) ($0.96) ($0.94) ($0.93) ($0.89) ($1.01) ($0.94) ($0.85) ($0.83) ($0.78)
Adjusted Weighted Average Basic Shares Outstanding		 93.10M 80.78M 80.09M 79.01M 72.29M 58.07M 56.81M 54.28M 53.91M 51.98M 53.77M
Adjusted Diluted Earnings per Share		 ($1.04) ($0.86) ($0.96) ($0.94) ($0.93) ($0.89) ($1.01) ($0.94) ($0.85) ($0.83) ($0.78)
Adjusted Weighted Average Diluted Shares Outstanding		 93.10M 80.78M 80.09M 79.01M 72.29M 58.07M 56.81M 54.28M 53.91M 51.98M 53.77M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 93.68M 93.05M 92.74M 80.04M 78.86M 69.60M 66.80M 54.69M 54.03M 53.91M 53.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -78 -66 -61 -58 -51 -44 -41 -37 -34 -33 -30
Normalized NOPAT Margin		 -21,602.08% 0.00% 0.00% -14,523.33% -8,042.23% 0.00% -11,931.76% -3,754.71% -1,253.62% -4,695.23% -6,641.44%
Pre Tax Income Margin		 -26,807.20% 0.00% 0.00% -18,560.15% -10,418.59% 0.00% -16,606.36% -5,159.82% -1,714.82% -6,352.75% -9,153.93%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Crinetics Pharmaceuticals' Financials

When does Crinetics Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Crinetics Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Crinetics Pharmaceuticals' net income changed over the last 8 years?

Crinetics Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$298.41 million in 2024, rising from -$6.02 million in 2016. The previous period was -$214.53 million in 2023. See where experts think Crinetics Pharmaceuticals is headed by visiting Crinetics Pharmaceuticals' forecast page.

What is Crinetics Pharmaceuticals's operating income?
Crinetics Pharmaceuticals's total operating income in 2024 was -$338.85 million, based on the following breakdown:
  • Total Gross Profit: $1.04 million
  • Total Operating Expenses: $339.89 million
How has Crinetics Pharmaceuticals revenue changed over the last 8 years?

Over the last 8 years, Crinetics Pharmaceuticals' total revenue changed from $589 thousand in 2016 to $1.04 million in 2024, a change of 76.4%.

How much debt does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals' total liabilities were at $109.79 million at the end of 2024, a 14.1% increase from 2023, and a 11,833.4% increase since 2017.

How much cash does Crinetics Pharmaceuticals have?

In the past 6 years, Crinetics Pharmaceuticals' cash and equivalents has ranged from $14.19 million in 2017 to $264.55 million in 2024, and is currently $264.55 million as of their latest financial filing in 2024.

How has Crinetics Pharmaceuticals' book value per share changed over the last 8 years?

Over the last 8 years, Crinetics Pharmaceuticals' book value per share changed from 0.00 in 2016 to 14.29 in 2024, a change of 1,428.6%.


Related Companies

This page (NASDAQ:CRNX) was last updated on 5/25/2025 by MarketBeat.com Staff
From Our Partners
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...
Crypto 101 Media | Sponsored
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...
Crypto Swap Profits | Sponsored
Massive new energy source found in Utah
NEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...
Stansberry Research | Sponsored